地努图希单抗β靶向GD2是治疗恶性胶质瘤有前景的免疫治疗途径
本研究分析原发胶质母细胞瘤(GBM)细胞系GD2与补体调节蛋白(CD46、CD55、CD59)表达,并用钙黄绿素AM法检测地努图希单抗β介导的ADCC与CDC。结果显示多数GBM细胞可被ADCC杀伤,CDC抵抗细胞高表达补体调节蛋白,提示GD2靶向联合补体调节蛋白阻断可能为GBM治疗选择。
要点
- 原发GBM细胞GD2表达异质,肿瘤表面表达高于核心来源细胞。
- 地努图希单抗β对多数GBM细胞介导ADCC,CDC作用不明显。
- CDC抵抗细胞高表达CD46、CD55和CD59,联合补体调节蛋白阻断或为治疗选择。
核心结论
- 地努图希单抗β对GBM细胞具有抗肿瘤效应,为GD2靶向免疫治疗GBM提供依据。
- 由于补体调节蛋白高表达,GD2靶向联合补体调节蛋白阻断可能成为GBM的进一步治疗选择。
研究设计与样本
- 研究为体外实验,采用流式细胞术分析已知及新建立的原发肿瘤来源GBM细胞系GD2与补体调节蛋白(CD46、CD55、CD59)表达。
- 采用非放射性钙黄绿素AM法检测地努图希单抗β介导的抗体依赖细胞介导细胞毒作用(ADCC)与补体依赖细胞毒作用(CDC)。
主要发现
- 原发GBM细胞GD2表达异质,各细胞系间不同,肿瘤表面来源细胞表达高于核心来源细胞。
- 每个分析的细胞系中均同时检测到GD2阳性与阴性肿瘤细胞。
- 地努图希单抗β对多数GBM细胞介导ADCC,而未观察到CDC作用。
- CDC抵抗细胞高表达补体调节蛋白CD46、CD55和CD59。
临床怎么用
- 作者认为地努图希单抗β对GBM细胞的抗肿瘤效应为GD2靶向免疫治疗GBM提供依据。
- 作者认为由于补体调节蛋白高表达,GD2靶向联合补体调节蛋白阻断可能为GBM的进一步治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Disialoganglioside GD2 is expressed by glioblastoma multiforme (GBM) cells representing a promising target for anti-GD2 immunotherapeutic approaches. The aim of the present study was to investigate anti-tumor efficacy of the chimeric anti-GD2 antibody (Ab) dinutuximab beta against GBM. METHODS: Expression levels of GD2 and complement regulatory proteins (CRP; CD46, CD55 and CD59) on well-known and newly established primary tumor originated GBM cell lines were analyzed by flow cytometry. Ab-dependent cellular (ADCC) and complement-dependent cytotoxicity (CDC) mediated by dinutuximab beta against GBM cells were determined by a non-radioactive calcein-AM-based assay. RESULTS: Analysis of primary GBM cells revealed a heterogeneous GD2 expression that varied between the cell lines analyzed with higher expression levels in the tumor surface compared to the core originated cells. Both GD2-positive and -negative tumor cells were detected in every cell line analyzed. In contrast to CDC, ADCC mediated by dinutuximab beta was observed against the majority of GBM cells. Importantly, CDC-resistant cells showed high expression of the CRP CD46, CD55 and CD59. CONCLUSION: Our present data show anti-tumor effects mediated by dinutuximab beta against GBM cells providing a rationale for a GD2-directed immunotherapy against GBM. Due to high CRP expression, a combining of GD2-targeting with CRP blockade might be a further treatment option for GBM.
引用
- Marx S, Wilken F, Wagner I, et al. GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma. J Neurooncol. 2020. PMID: 32246395. doi:10.1007/s11060-020-03470-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。